EVOK Dividend: Evoke Pharma Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

EVOK Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	14	10	5	2	1	0
Revenue Growth (YoY)	75%	100%	150%	100%	--	--
Cost of Revenue	0	0	0	0	0	0
Gross Profit	13	9	4	2	1	0
Selling, General & Admin	19	15	12	9	8	6
Research & Development	0	0	0	0	0	6
Operating Expenses	19	15	12	9	9	12
Other Non Operating Income (Expenses)	--	--	--	0	0	--
Pretax Income	-5	-5	-7	-8	-8	-13
Income Tax Expense	--	--	--	--	--	--
Net Income	-5	-5	-7	-8	-8	-13
Net Income Growth	-17%	-28.99%	-13%	0%	-38%	86%
Shares Outstanding (Diluted)	2.55	1.9	0.27	3.14	2.68	2.12
Shares Change (YoY)	83%	584%	-91%	17%	26%	14%
EPS (Diluted)	-2.04	-2.8	-27.97	-2.62	-3.18	-6.19
EPS Growth	-54%	-90%	968%	-18%	-49%	61%
Free Cash Flow	-3	-5	-4	-6	-12	-6
Free Cash Flow Per Share	-1.17	-2.62	-14.35	-1.91	-4.47	-2.83
Gross Margin	92.85%	90%	80%	100%	100%	0%
Operating Margin	-35.71%	-50%	-140%	-350%	-800%	0%
Profit Margin	-35.71%	-50%	-140%	-400%	-800%	0%
Free Cash Flow Margin	-21.42%	-50%	-80%	-300%	-1,200%	0%
EBITDA	--	--	--	--	--	--
EBITDA Margin	--	--	--	--	--	--
D&A For EBITDA	--	--	--	--	--	--
EBIT	-5	-5	-7	-7	-8	-13
EBIT Margin	-35.71%	-50%	-140%	-350%	-800%	0%
Effective Tax Rate	--	--	--	--	--	--